- Home
- DAVE vs ZYME Comparison
DAVE vs ZYME Comparison
Compare DAVE & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAVE
- ZYME
- Stock Information
- Founded
- DAVE 2017
- ZYME 2003
- Country
- DAVE United States
- ZYME United States
- Employees
- DAVE N/A
- ZYME N/A
- Industry
- DAVE Retail: Computer Software & Peripheral Equipment
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- DAVE Technology
- ZYME Health Care
- Exchange
- DAVE Nasdaq
- ZYME Nasdaq
- Market Cap
- DAVE 795.6M
- ZYME 751.6M
- IPO Year
- DAVE N/A
- ZYME 2017
- Fundamental
- Price
- DAVE $80.06
- ZYME $15.39
- Analyst Decision
- DAVE Strong Buy
- ZYME Buy
- Analyst Count
- DAVE 6
- ZYME 5
- Target Price
- DAVE $78.00
- ZYME $19.00
- AVG Volume (30 Days)
- DAVE 616.6K
- ZYME 572.6K
- Earning Date
- DAVE 11-12-2024
- ZYME 10-31-2024
- Dividend Yield
- DAVE N/A
- ZYME N/A
- EPS Growth
- DAVE N/A
- ZYME N/A
- EPS
- DAVE 3.12
- ZYME N/A
- Revenue
- DAVE $319,355,000.00
- ZYME $62,199,000.00
- Revenue This Year
- DAVE $26.58
- ZYME $30.09
- Revenue Next Year
- DAVE $18.48
- ZYME N/A
- P/E Ratio
- DAVE $25.67
- ZYME N/A
- Revenue Growth
- DAVE 30.00
- ZYME N/A
- 52 Week Low
- DAVE $5.60
- ZYME $7.80
- 52 Week High
- DAVE $94.96
- ZYME $17.70
- Technical
- Relative Strength Index (RSI)
- DAVE 75.16
- ZYME 55.74
- Support Level
- DAVE $37.44
- ZYME $12.39
- Resistance Level
- DAVE $94.96
- ZYME $17.70
- Average True Range (ATR)
- DAVE 5.12
- ZYME 0.84
- MACD
- DAVE 4.64
- ZYME 0.10
- Stochastic Oscillator
- DAVE 74.10
- ZYME 56.50
About DAVE Dave Inc.
Dave Inc is a financial services company. It is engaged in offering banking app that offers its customers banking, financial insights, overdraft protection, building credit, and finding side gigs.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.